MCRB Seres Therapeutics
- 1.191
- +0.001+0.09%
Seres Therapeutics News
Oppenheimer Sticks to Its Buy Rating for Seres Therapeutics (MCRB)
Chardan Capital Maintains Buy on Seres Therapeutics, Lowers Price Target to $8
Seres Therapeutics (MCRB) Gets a Buy From TD Cowen
Sell Rating on Seres Therapeutics Amid Underperforming Sales and Financial Challenges
Seres Therapeutics Analyst Ratings
Oppenheimer Trims Seres Therapeutics Price Target to $9 From $10, Maintains Outperform Rating
Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB) and Seres Therapeutics (MCRB)
Goldman Sachs Maintains Sell on Seres Therapeutics, Lowers Price Target to $1.25
Seres Therapeutics Analyst Ratings
Oppenheimer Adjusts Seres Therapeutics Price Target to $10 From $12, Maintains Outperform Rating
Oppenheimer Sticks to Its Buy Rating for Seres Therapeutics (MCRB)
Buy Rating for Seres Therapeutics: A Review of Vowst's Success, Restructuring, and SER-155 Prospects
Sell Rating on Seres Therapeutics Amidst Restructuring and Financing Risk Concerns
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Irhythm Technologies (IRTC) and Seres Therapeutics (MCRB)
Analysts' Top Healthcare Picks: Seres Therapeutics (MCRB), Phathom Pharmaceuticals (PHAT)
Seres Therapeutics (MCRB) Receives a Sell From Goldman Sachs
Analysts' Top Healthcare Picks: Seres Therapeutics (MCRB), Inmune Bio (INMB)
Oppenheimer Assumes Seres Therapeutics at Outperform, Announces Price Target of $12
Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB) and Agenus (AGEN)
Seres Therapeutics (MCRB) Gets a Buy From Chardan Capital
Analysis
Price Target
No Data
